Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021

Basit Öğe Kaydı
dc.authorid0000-0003-0906-4417
dc.contributor.authorFankhauser, Christian Daniel
dc.contributor.authorOldenburg, Jan
dc.contributor.authorAlbers, Peter
dc.contributor.authorAlgaba, Ferran
dc.contributor.authorBokemeyer, Carsten
dc.contributor.authorBoormans, Joost L.
dc.contributor.authorFischer, Stefanie
dc.contributor.authorFizazi, Karim
dc.contributor.authorGremmels, Hendrik
dc.contributor.authorMayor de Castro, Javier
dc.contributor.authorJanisch, Florian
dc.contributor.authorMuilwijk, Tim
dc.contributor.authorLeao, Ricardo
dc.contributor.authorNicol, David
dc.contributor.authorNicolai, Nicola
dc.contributor.authorTandstad, Torgrim
dc.contributor.authordel Pilar Laguna Pes, Maria
dc.date.accessioned2021-08-02T08:52:49Z
dc.date.available2021-08-02T08:52:49Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractRecent randomized controlled trials have assessed the risksand benefits of thromboprophylaxis in ambulatory cancerpatients receiving chemotherapy and reported a relativerisk reduction of 30–60% in venous thromboembolic events(VTEs) but a doubling of bleeding risk [1–4]. Based on theseresults, the most recent American Society of ClinicalOncology clinical practice guideline update recommendsthromboprophylaxis with apixaban, rivaroxaban, or low-molecular–weight heparin (LMWH) for cancer patientswith a high risk of VTE and low risk of bleeding [5]. Patientswith metastatic germ-cell tumor (mGCT) were under-represented in all trials and thus it is not clear whether thisrecommendation applies to this group, although retrospec-tive data suggests similar efficacy of VTE prophylaxis.
dc.identifier.citationFankhauser, C. D., Oldenburg, J., Albers, P., Algaba, F., Bokemeyer, C., Boormans, J. L. ... del Pilar Laguna Pes, M. (2021). Recommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. European Urology, 80(1), 4-6. https://dx.doi.org/10.1016/j.eururo.2021.02.032
dc.identifier.doi10.1016/j.eururo.2021.02.032
dc.identifier.endpage6
dc.identifier.issn0302-2838
dc.identifier.issn1873-7560
dc.identifier.issue1
dc.identifier.scopusqualityQ1
dc.identifier.startpage4
dc.identifier.urihttps://dx.doi.org/10.1016/j.eururo.2021.02.032
dc.identifier.urihttps://hdl.handle.net/20.500.12511/7641
dc.identifier.volume80
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean Urologyen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectBalance Benefits
dc.subjectRisks of Thromboprophylaxis
dc.subjectMetastatic Germ Cell Tumors
dc.subjectEuropean Association Of Urology Testicular Cancer Panel Position in 2021
dc.titleRecommendations to balance benefits and risks of thromboprophylaxis and to avoid central venous-access devices during first-line chemotherapy in men with metastatic germ cell tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
dc.typeEditorial

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Laguna-M-2021.pdf
Boyut:
1.1 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu